Heparin-induced thrombocytopenia

100,051views

Heparin-induced thrombocytopenia

BIIC

BIIC

Thymus histology
Spleen histology
Lymph node histology
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Blood histology
Blood components
Blood groups and transfusions
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
von Hippel-Lindau disease
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Pyruvate kinase deficiency
Hereditary spherocytosis
Beta-thalassemia
Alpha-thalassemia
Iron deficiency anemia
Anemia of chronic disease
Sickle cell disease (NORD)
Erythropoietin
Hemophilia
Vitamin K deficiency
Von Willebrand disease
Sideroblastic anemia
Autoimmune hemolytic anemia
Paroxysmal nocturnal hemoglobinuria
Aplastic anemia
Fanconi anemia
Folate (Vitamin B9) deficiency
Vitamin B12 deficiency
Megaloblastic anemia
Diamond-Blackfan anemia
Lead poisoning
Bernard-Soulier syndrome
Hemolytic-uremic syndrome
Thrombotic thrombocytopenic purpura
Immune thrombocytopenia
Glanzmann's thrombasthenia
Disseminated intravascular coagulation
Heparin-induced thrombocytopenia
Antithrombin III deficiency
Protein C deficiency
Antiphospholipid syndrome
Factor V Leiden
Protein S deficiency
Polycythemia vera (NORD)
Mixed platelet and coagulation disorders: Pathology review
Coagulation disorders: Pathology review
Macrocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Platelet disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Myeloproliferative disorders: Pathology review
Anticoagulants: Heparin
Anticoagulants: Warfarin
Thrombolytics
Hematopoietic medications
Protein synthesis inhibitors: Tetracyclines
DNA synthesis inhibitors: Fluoroquinolones
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
Protein synthesis inhibitors: Aminoglycosides
Yellow fever virus
Dengue virus
Ebola virus
Hantavirus
Salmonella typhi (typhoid fever)
Yersinia pestis (Plague)
Borrelia burgdorferi (Lyme disease)
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Coxiella burnetii (Q fever)
Ehrlichia and Anaplasma
Hodgkin lymphoma
Non-Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelodysplastic syndromes
Myelofibrosis (NORD)
Essential thrombocythemia (NORD)
Multiple myeloma
Waldenstrom macroglobulinemia
Leukemias: Pathology review
Lymphomas: Pathology review
Plasma cell disorders: Pathology review
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
HIV and AIDS: Pathology review
HIV (AIDS)
Integrase and entry inhibitors
Protease inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

Transcript

Watch video only

The term heparin-induced thrombocytopenia can be divided into two parts.

Heparin refers to an anticoagulant medication which prevents blood clots from forming, and thrombocytopenia refers to decreased number of thrombocytes, or platelets, in the blood.

So, heparin-induced thrombocytopenia or, HIT, is a complication caused by heparin that results in decreased platelets in the blood.

Okay, so imagine you’re making dinner and accidentally cut one of your fingers.

Now, if your body doesn’t stop the bleeding, you will keep losing blood until there’s not enough to supply the vital organs like the heart and brain.

Now to prevent this from happening the body has a process called hemostasis.

This process has two phases: primary and secondary hemostasis.

In primary hemostasis, platelets aggregate to form a plug at the site of an injured blood vessel.

While these platelets are aggregating, coagulation, or secondary hemostasis starts.

This is where numerous enzymes that are always floating around in the blood called clotting factors get proteolytically activated, meaning that activation happens when a small piece is chopped off - a bit like pulling the pin out of a grenade.

These factors activate one another, eventually leading to the activation of fibrin or factor Ia.

That results in a fibrin mesh which forms around the platelet plug to reinforce it and hold it together.

Without primary and secondary hemostasis, our body would suffer massive blood loss from even the most minor injuries; imagine losing all of your blood from something as simple as a pinprick!

Okay, so heparin induced thrombocytopenia is caused by heparin.

This medication works by activating an enzyme called antithrombin III, which inhibits coagulation factors Xa, also known as thrombin.

This halts secondary hemostasis and prevents existing blood clots from growing larger, so it’s often given to people who suffer from pulmonary embolisms, strokes, and myocardial infarctions.

Now, the main mechanism behind the development of HIT is actually an immune response, which starts when heparin binds to a protein on the surface of inactivated platelets called platelet factor 4 or PF-4. Together they form a complex called heparin-PF4 complex.

This complex is immunogenic in certain people, meaning they have circulating IgG antibodies that recognize the complex as foreign pathogens.

So these antibodies will bind to the heparin-PF4 complex and mark it for destruction within the spleen.

Now when the antibody binds, it causes the platelet to activate.

The activated platelets release procoagulant chemicals like thromboxane A2 or TXA2, which causes other platelets to activate.

At the same time, the original platelet will also release more PF-4s so more antibodies will bind and keep it activated.

These events leads to more and more platelets getting activated and they start forming clots throughout the body.

This way, a lot of the remaining platelets also get consumed, which results in a low platelet count.

Key Takeaways

Heparin-induced thrombocytopenia (HIT) is a rare but potentially life-threatening complication that can occur during the treatment course with heparin. HIT occurs when the body produces antibodies against heparin, which then attach to and damage platelets (the cells that help the blood clot). This can decrease the number of platelets in the blood (thrombocytopenia), which can cause easy bruising and bleeding.

Sources

  1. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  2. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  3. "Yen & Jaffe's Reproductive Endocrinology" Saunders W.B. (2018)
  4. "Bates' Guide to Physical Examination and History Taking" LWW (2016)
  5. "Robbins Basic Pathology" Elsevier (2017)
  6. "Heparin-induced thrombocytopenia: an update" Thrombosis Journal (2005)
  7. "Signaling During Platelet Adhesion and Activation" Arteriosclerosis, Thrombosis, and Vascular Biology (2010)
  8. "von Willebrand Disease in the Pediatric and Adolescent Population" Journal of Pediatric and Adolescent Gynecology (2010)